drugset
drugset / Trial / NCT03407404

Comparing Clinical Outcomes Between Ketamine-midazolam and Morphine-midazolam for Continous Sedation in ICU Patients.

NCT03407404 ↗

Phase 2/3 Terminated 124 enrolled Makerere University THRiVE · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

A prospective, double-blinded, multicenter randomized control trial. All critically ill patients above 12 years of age requiring continuous sedation for \>24hrs in the ICU will be screened and those meeting selection criteria (and consented) will be enrolled into the study. .

Timeline

Start
2017-10-22
Primary completion
2019-06-15
Completion
2019-07-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Ketamine Small molecule 900 mg Intravenous
Subject Morphine Other / unclassified 54 mg Intravenous
Background Midazolam Small molecule 36 mg Intravenous

Indications

No indication recorded.